期刊文献+

人源抗菌肽LL-37的原核表达及活性鉴定 被引量:3

Prokaryotic Expression and Activities of Human Antimicrobial Peptide LL-37
原文传递
导出
摘要 目的:实现大肠杆菌高效可溶表达人源抗菌肽LL-37。方法:LL-37基因克隆至原核载体pET32a,于大肠杆菌BL21(DE3)中诱导表达。运用相关生物信息学软件分析重组蛋白Trx-LL-37的理化性质、亲/疏水性、蛋白质二级结构及其可溶表达概率。实验还考察了不同诱导温度对重组蛋白可溶表达比例的影响。结果:生物信息学分析显示,Trx-LL-37分子量21.5kD,理论等电点6.3,物理性质稳定,二级结构简单,具有可溶表达倾向。重组蛋白最佳诱导温度为17℃,与37℃相比,可溶表达比例由37.2%提高至50.2%,并且总表达量也提高了5%左右。抑菌结果显示纯化产物对多种常见细菌的生长具有抑制作用。结论:可采用融合方式通过原核系统高效可溶表达LL-37,为LL-37的功能研究打下基础。 Objective:The article was designed to highly express soluble human antibacterial peptide LL-37 in E.coli.Method:The DNA sequence encoding LL-37 was cloned into the pET32a vector and expressed in E.coli strain BL21(DE3).The physical-chemical properties,hydrophilicity or hydrophobicity,the secondary structure and the soluble expression probability of Trx-LL-37 were analyzed with bioinformatics analysis software.The effect of temperature on the proportion of soluble expression was also investigated in this experiment.Result:Bioinformatic analysis showed that,physical properties of Trx-LL-37 was stable,the secondary structure was simple,and Trx-LL-37 had the tendency to be expressed in a soluble way.Further optimization studies showed that the expression system was very efficient to produce soluble target protein at 17℃.Compared to 37℃,the percentage in total soluble protein of Trx-LL-37 was increased from 37.2% to 50.2%,and the expression level of Trx-LL-37 was increased by 5%.In terms of antibacterial activity,the purified product was able to inhibit the growth of common pathogens.Conclution:The results established that LL-37,human antibacterial peptide,was successfully expressed by the prokaryotic expression system in a soluble way at low induced temperature.
出处 《生物技术》 CAS CSCD 北大核心 2012年第1期18-22,共5页 Biotechnology
基金 广州市科技支撑计划项目(No.2010J-E411)资助
关键词 人源抗菌肽LL-37 生物信息学分析 原核表达 低温诱导 抑菌活性 human antimicrobial peptide LL-37 bioinformatics analysis prokaryotic expression low-temperature induction antibacterial activity
  • 相关文献

参考文献10

  • 1Strominger J L.Animal antimicrobial peptides:ancient players in innate immunity[J].J Immunol,2009,182(11):6633-6634.
  • 2黎观红,洪智敏,贾永杰,瞿明仁.抗菌肽的抗菌作用及其机制[J].动物营养学报,2011,23(4):546-555. 被引量:91
  • 3Méndez-Samperio P.The human cathelicidin hCAP18/LL-37:A multifunctional peptide involved in mycobecterial infections[J].Peptides,2010,31 (9):1791-1798..
  • 4Mookherjee N,Lippert DN,Hamill P,et al.Intracellular receptor for human host defense peptide LL-37 in monocytes[J].J Immunol,2009,183(4):2688-2696.
  • 5Kai-Larsen Y,Agerberth B.The role of multifunctional peptide LL-37 in host defense[J].Front Biosci,2008,13(10):3760-3767.
  • 6Jacobsen F,Mittler D,Hirseh T,et al.Transient cutaneous adenoviral gene therapy with human host defense peptide hCAP-18/LL-37 is effective for the treatment of burn wound infections[J].Gene Ther,2005,12(20):1494-1502.
  • 7张颋,王菊芳,冯延叶,杨忠,马骊,王小宁.可溶性预测模型在包涵体复性中的应用[J].南方医科大学学报,2009,29(11):2156-2160. 被引量:5
  • 8Vidovic V,Prongidi-Fix L,Bechinger B,et al.Production and isotope labeling of antimicrobial peptides in Escherichia coli by means of a novel fusion partner that enables high-yield insoluble expression and fast purification[J].J Pept Sci,2009,15(4):278-284.
  • 9Ramos R,Domingues L,Gama M.Escherichia col(i) expression and purification of LL37 fused to a family Ⅲ carbohydrate-binding module from Clostridium thermocellum[J].Protein Expr Purff.,2010,71 (1):1-7.
  • 10Moon JY,Henzler-Wildman KA,Ramamoorthy A.Expression and purification of a recombinant LL-37 from Escherichia coli.[J].Biochim Biophys Acta,2006,1758(9):1351-1358.

二级参考文献67

  • 1周联,俞瑜,王培训.防御素与先天性免疫及获得性免疫[J].国外医学(免疫学分册),2005,28(2):68-72. 被引量:23
  • 2Baneyx F. Recombinant protein expression in Escherichia coli[J]. Curr Opin Biotechnol, 1999, 10(5): 411-21.
  • 3Sahdev S, Khattar SK, Saini KS. Production of active eukatyotic proteins through bacterial expression systems: a review of the existing biotechnology strategies [ J ]. Mol Cell Biochem, 2008, 307 (1-2): 249-64.
  • 4Rudolph R, Lilie H. In vitro folding of inclusion body proteins [J]. FASEB J, 1996, 10(1): 49-56.
  • 5Marston SB. Ca^2+ can control vascular smooth-muscle thin filaments without ealdesmon phosphorylation [J]. Bioehem J, 1986, 237(2): 605-7.
  • 6Vallejo LF, Rinas U. Optimized procedure for renaturation of recombinant human bone morphogenetic protein-2 at high protein concentration [J]. Biotechnol Bioeng, 2004, 85(6): 601-9.
  • 7Carrio M, Gonzalez-Montalban N, Vera A, et al. Amyloid-like properties of bacterial inclusion bodies [J]. J Mol Biol, 2005, 347 (5): 1025-37.
  • 8Koschorreck M, Fischer M, Barth S, et al. How to find soluble proteins: A comprehensive analysis of alpha/beta hydrolases for recombinant expression in E. coli [J]. BMC Genomies, 2005, 6(1): 49.
  • 9Wetzel R, Perry LJ, Veilleux C. Mutations in human interferon gamma affecting inclusion body formation identified by a general immunochemical screen [ J ]. Biotechnology (N Y), 1991, 9(8): 731-7.
  • 10King J, Haase-Pettingell C, Robinson AS, et al. Thermolabile folding intermediates: Inclusion body precursors and chaperonin substrates [J]. FASEB J, 1996, 10(1): 57-66.

共引文献94

同被引文献23

  • 1Yano J, Noverr MC, Fidel PL Jr. Cytokines in the host response to Candida vaginitis: Identifying a role for non-classical immune mediators, S100 alarmins[J]. Cytokine, 2012, 58(1):118-128. DOI: 10.1016/j.cyto.2011.11.021.
  • 2Ilkit M, Guzel AB. The epidemiology, pathogenesis, and diagnosis of vulvovaginal candidosis: a mycological perspective[J]. Crit Rev Microbiol, 2011, 7(3):250-261. DOI: 10.3109/1040841X.2011.576332.
  • 3Nijnik A, Hancock RE. The roles of cathelicidin LL-37 in immune defenees and novel clinical applications[J]. Curt Opin Hematol, 2009, 16(1):41-47.
  • 4Kahlenberg JM, Kaplan MJ. Little peptide, big effects: the role of LL-37 in inflammation and autoimmune disease[J]. J Immunol, 2013, 191(10):4895-4901. DOI: 10.4049/jimmunol. 1302005.
  • 5Wang G, Mishra B, Lau K, et al.Antimicrobial peptides in 2014[J]. Pharmaceuticals (Basel), 2015, 8(1):123-150. DOI: 10.3390/ph8010123.
  • 6Zhang X, Ogl~cka K, Sandgren S, et al. Dual functions of the human antimicrobial peptide LL-37-target membrane perturbation and host cell cargo delivery[J]. Biochim Biophys Acta, 2010, 1798(12):2201-2208. DOI:10.1016/j.bbamem. 2009.12.011.
  • 7Reinholz M, Ruzicka T, Schauber J. Cathelicidin LL-37: an antimicrobial peptide with a role in inflammatory skin disease [J]. Ann Dermatol, 2012, 24(2):126-135. DOI: 10.5021/ ad.2012.24.2.126.
  • 8Srakaew N, Young CD, Sae-wu A, et al. Antimicrobial host defence peptide, LL-37, as a potential vaginal contraceptive [J]. Hum Reprod, 2014, 29(4):683-696. DOI: 10.1093/humrep/ deu018.
  • 9Rapala~Kozik M, Bochenska O, Zawrotniak M, et al. Inactivation of the antifungal and immunomodulatory properties of human cathelicidin LL-37 by aspartic proteases produced by the pathogenic yeast Candida albicans[J]. Infect Immun, 2015, 83(6):2518-2530. DOI: 10.1128/IAI.00023-15.
  • 10叶湘,张真,王群兴,吴晓玲.妇产科假丝酵母菌性阴道炎的菌种分布及耐药性[J].中华医院感染学杂志,2012,22(5):1081-1082. 被引量:14

引证文献3

二级引证文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部